On Jan. 05, Veness Adam M divested U.S. $251,988 in shares of Acceleron Pharma Inc.. The SVP, GC, Sec. sold 2,056 shares at a price per share of $122.56. The transaction decreased this specific insider’s holdings to 16,163 shares worth around $1.98 million at present.
Another 10,000 shares were sold by Kango Sujay, for more than $1,253,759 in total proceeds. The EVP, Chief Commercial Officer dumped the shares at a price of $125.38 and the insider now owns almost 3,987 shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
That same day, McLaughlin Kevin F sold 4,779 shares. The SVP, CFO, Treasurer divested U.S. $588,974 in shares of Acceleron Pharma Inc. at a price per share of $123.24. The transaction decreased this specific insider’s holdings to 5,813 shares worth around $711394.94 at present.
Dable Habib J sold 4,258 shares. The CEO, Pres divested U.S. $515,774 in shares of Acceleron Pharma Inc. at a price per share of $121.13. The transaction decreased this specific insider’s holdings to 81,788 shares worth around $10009215.44 at present.
H.C. Wainwright maintained its Acceleron Pharma Inc. [XLRN] rating to the equivalent of a Buy but changed the price target to $148 from $137, in a research note dated November 06, 2020. That figure represents around a 17.31% premium from where the company’s shares closed on Wednesday. Other analysts also revised their coverage, with H.C. Wainwright’s analysts reiterating the shares to “a Buy” rating in a research note to investors issued in early November. Meanwhile, Raymond James had launched its coverage on XLRN with “Strong buy”, in a research note produced for clients August 25, 2020. In addition, there was a downgrade from Goldman on April 06, 2020. The rater changed XLRN from “a Neutral” to “a Sell”.
Is Acceleron Pharma Inc. [NASDAQ:XLRN] a Good Buy Right Now?
It should be noted that XLRN technical indicators for short, intermediate as well as long term progress have placed an overall average of 80% as Buy. The average signal changed from 88% Buy in the last week and compares with 100% Buy in the past month. Data from Acceleron Pharma Inc.’s Trend Spotter indicated that the signals were Falling. The stock current average is 0.32 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 0.28 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.33 million shares.
XLRN Price Performance
On Wall Street, Acceleron Pharma Inc. [NASDAQ:XLRN] finished Wednesday’s session down -0.12% at $122.38. The stock went up to $122.41 at the same session while its lowest single day price was $119.07. In the last five days, it saw a fall of about -2.42%, Acceleron Pharma Inc. shares dropped by almost -4.35% since the beginning of the year. However, the share price has dropped to as low as -10.18% below its one year high. On 01/04/21, the company shares recorded $127.00, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/06/21, the same year at $119.07. The company’s shares have inclined by 138.33% in the past year. The 50-day SMA achieved is $118.83 while the 200-day SMA is $104.11. Volume gained to 0.45 million from 0.23 million in the previous session.
Acceleron Pharma Inc. [XLRN] Valuation Measures
Notably, Acceleron Pharma Inc. [XLRN] stock can be helpful for investors to consider historical price-sales ratio, more specifically, a 69.50 PS value ratio is reported for the last one year of reported earnings. That is higher than the industry average of 20.33.
XLRN Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 120.16 level, and in case of violation of this particular level, it will cause more drop to 117.95 level. On the upper level, 124.63 is still the key resistance. The stock may increase to the subsequent resistance at 123.50. The Relative Strength Index (RSI) pinned on the 14-day chart is 45.70, implying a neutral technical stance while the MACD stands at -5.59, meaning price will decrease in the next trading period. Percent R indicator moved to 80.73%, implying bearish price movement. Stochastic %K at 15.81% suggest buying the stock.
What is the short interest in Acceleron Pharma Inc.?
Short interest in the Acceleron Pharma Inc. stock has surged, increasing by 0.58 million shares to total 2.93 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 3.51 million, data from Yahoo Finance shows. The decrease of -19.8% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 6.48% of the overall float for the stock.
Acceleron Pharma Inc.’s Biggest Shareholders: Who Owns Acceleron Pharma Inc. [XLRN]?
Filings by Fidelity Management & Research Co showed that the firm now holds a total of 5,480,188 shares or roughly 9.10% of the outstanding XLRN shares. This means their shares have reduced by -1,564,375 from the 5,480,188 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, T. Rowe Price Associates, Inc. updated stake is worth $613,417,690. Details in the latest 13F filings reveal that The Vanguard Group, Inc. acquired their 8.44% stake valued at $545,563,570 while BlackRock Fund Advisors added theirs at $315,026,227. During the last quarter, The Vanguard Group, Inc. raised 359,656 of its shares in Acceleron Pharma Inc. while BlackRock Fund Advisors bought 152,587 shares. The Farallon Capital Management LLC’s holdings currently number 2,600,000 shares at $318188000.0. According to the firm’s last 13F report, Janus Capital Management LLC shares in the company at filing stood at 1,783,939 shares, roughly $210,629,678.
XLRN Earnings Forecast For The Current Quarter
Acceleron Pharma Inc. [XLRN] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $32.73M and an earnings per share of -$0.57 for Dec 2020. Looking further ahead, the company is expected to report revenue of $30.44M at an EPS of -$0.64 for Mar 2021. The estimates represent downside of 68.80% and 20.60% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
XLRN Earnings Estimates For The Current Year
For the financial year, Acceleron Pharma Inc. [NASDAQ:XLRN] is expected to bring in revenue of $98.23M. The returns are nearly $24.24 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -2.52, lower than that of FY19 by -$0.14. Estimates put this year’s earnings growth at -5.90%, 20.60% for the next. As for sales, forecasts are for an increase of 32.80% in the current fiscal year and a further 68.80% over the following year.
What are analyst thoughts on Acceleron Pharma Inc.?
Looking forward to the Acceleron Pharma Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Acceleron Pharma Inc. stock at $135.00 within the next 12 months, which represents almost 9.35 per cent growth from its previous closing price of $122.38. The highest analysts’ target for Acceleron Pharma Inc. stock projections is $155.00 and the lowest one is $100.00. Still, 13 analysts sharing their consensus rating for XLRN stock in 2021 agree that it is a Buy.